<DOC>
	<DOCNO>NCT02117128</DOCNO>
	<brief_summary>We investigate efficacy safety use tranexamic acid intravenous , intra-articular combinational administration reduce blood loss total knee replacement . We hypothesize combine intra-articular single intravenous dose protocol tranexamic acid may achieve high therapeutic concentration intra-articular extra-articular bleeding site little systemic absorption subsequent systemic side effect .</brief_summary>
	<brief_title>The Efficacy Safety Using Tranexamic Acid Different Means Reduce Blood Loss During Total Knee Replacement</brief_title>
	<detailed_description>A randomized , double-blind , single-center , control parallel-assigned study compare efficacy safety intravenous , intra-articular combinational administration tranexamic acid reduce blood loss total knee replacement . Subjects monitor occurrence complication , particularly deep venous thrombosis thromboembolism hospital stay 3 month postoperatively .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>Adult patient plan undergo primary total knee arthroplasty unilateral knee joint diagnosis osteoarthritis aseptic bone necrosis , rheumatoid arthritis ; All patient normal preoperative platelet count , normal prothrombin time , normal partial thromboplastin time , normal international normalized ratio ; The use balance electrolyte solution and/or albumin plasma volume restitution Allergy tranexamic acid ; Receiving warfarin heparin ; history hemophilia , deep venous thrombosis , pulmonary embolism , renal impairment ; pregnant ; Patients cardiovascular problem ( myocardiac infarction history , atrial fibrillation , angina ) ; Patients thromboembolic disorder , exhibit deteriorate general condition ; Preoperative anemia ( hemoglobin value &lt; 11 g/dL female &lt; 12 g/dL male ) , refusal blood product ; Preoperative use anticoagulant therapy within five day surgery , fibrinolytic disorder require intraoperative antifibrinolytic treatment , coagulopathy ( identify preoperative platelet count &lt; 150,000/mm3 , international normalize ratio &gt; 1.4 , prolong partial thromboplastin time [ &gt; 1.4 time normal ] ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Tranexamic Acid</keyword>
	<keyword>Antifibrinolytic</keyword>
	<keyword>Blood transfusion</keyword>
	<keyword>Total knee arthroplasty</keyword>
</DOC>